Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 32661059.
- Also identified by DOI 10.1126/science.abc6027 and PMC identifier 7402632.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-β and low IFN-α production and activity), which was associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor nuclear factor-κB and characterized by increased tumor necrosis factor-α and interleukin-6 production and signaling. These data suggest that type I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches.
Medical subject headings
- Betacoronavirus
- Coronavirus Infections
- Interferon alpha-2
- Interferon-alpha
- Interferon-beta
- Pneumonia, Viral